FDA pipeline preview, March 2008

FDA-related information through March 2008 on C1 inhibitor, ferric carboxymaltose injection, lovastatin, carbidopa/levodopa extended release, vigabatrin, bortezomib, peginterferon alfa-2b, elesclomol, triphendiol, VQD-002

Complete response letter

Recommended for approval

Nonapprovable designations

Fast-track designations

Priority review

Orphan drug designations